4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi

MIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayFebruary 25, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET. After the presentation, MetaVia management will open the floor for questions. Please submit your questions in ad

Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and intern

DeepMatcher® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform. Using AI-based compound-protein interaction modeling, Syntekabio has identif

CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.

CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants. The underwritten public

Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54 Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54 CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual ox

CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah. About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently devel

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed. About Met

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

4 - MetaVia Inc. (0001638287) (Issuer)

H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00